比较瑞舒伐他汀与辛伐他汀对老年冠心病患者血脂干预的效果  

Comparison of rosuvastatin and simvastatin in intervention of blood lipids in elderly patients with coronary heart disease

作　　者：刘健[1] 匡红英[2] 李群芳[1] 刘斌[1] 赵其辉[1] 蔡岳华[1] LIU Jian;KUANG Hong-ying;LI Qun-fang;LIU Bin;ZHAO Qi-hui;CAI Yue-hua(Medicine College in Hunan Institute of Environmental Biotechnology,Hengyang 421001,China;The First Affiliated Hospital of Nanhua University,Hengyang 421001,China)

机构地区：[1]湖南环境生物职业技术学院医学院,湖南衡阳421001 [2]南华大学附属第一医院,湖南衡阳421001

出　　处：《黑龙江医药科学》2019年第2期61-63,共3页Heilongjiang Medicine and Pharmacy

基　　金：衡阳市科技局资助一般项目;编号:2013KS65

摘　　要：目的:他汀类调脂药物是冠心病患者一线药物,该类药物的制剂类型有很多种,临床上对瑞舒伐他汀与辛伐他汀两种调脂药的效果比较的研究较少。方法:收集南华大学附属第一医院心内科住院的老年冠心病患者200例,将200例患者随机分为治疗组和对照组,治疗组使用瑞舒伐他汀每晚10mg口服,对照组使用辛伐他汀每晚10mg口服,均治疗8周,治疗前和治疗4周,8周后分别于早晨空腹抽静脉血,用酶法检测血清总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)水平,同时观察药物不良反应。结果:8周后瑞舒伐他汀组治疗后血浆LDL-C水平较辛伐他汀组明显下降(P<0.05),TC也明显下降(P<0.05)。两组降低TG的幅度相似,没有显著差异。瑞舒伐他汀、辛伐他汀组HDL-C水平升高,两组间差异有统计学意义(P<0.05)。结论:研究表明瑞舒伐他汀10mg/d较辛伐他汀10mg/d更有助于老年冠心病患者血脂尽快达到目标值,且可以产生更大程度的LDL-C下降,且横纹肌溶解发生概率低,肝肾功能的不良反应小。Objective:Statins are the first-line lipid-lowering drugs in patients with coronary heart disease.There are many types of lipid-lowering drugs.Methods:There are few comparative studies on the efficacy of rosuvastatin and simvastatin.200 elderly patients with coronary heart disease who were hospitalized in the Department of Cardiology of the First Affiliated Hospital of South China University were collected.200 patients were randomly divided into treatment group and control group.The treatment group were given rosuvastatin orally 10 mg per night,while the control group were given simvastatin orally 10 mg per night.All patients were treated for 8 weeks,before treatment and 4 weeks after treatment,respectively,in the morning after 8 weeks.Serum total cholesterol(TC),triglyceride(TG),high density lipoprotein cholesterol(HDL-C),low density lipoprotein cholesterol(LDL-C)were measured by enzyme method,and adverse drug reactions were observed.Results:After 8 weeks,the plasma LDL-C level in rosuvastatin group was significantly lower than that in simvastatin group(P<0.05),and TC was also significantly lower(P<0.05).There was no significant difference in amplitude of TG reduction between the two groups.The levels of HDL-C in rosuvastatin and simvastatin group were higher than in control group(P<0.05).Conclusion:This study showed that rosuvastatin 10mg/d was more helpful than simvastatin 10mg/d for the elderly patients with coronary heart disease to achieve the target blood lipid as soon as possible,and could produce a greater degree of LDL-C decline,and the incidence of rhabdomyolysis is low,and adverse reactions on liver and kidney are small.

关 键 词：瑞舒伐他汀 辛伐他汀 冠心病 血脂干预 

分 类 号：R541.4[医药卫生—心血管疾病]